SynthesisClinical cardiology2021

Kidney outcomes using a sustained ≥40% decline in eGFR: A meta-analysis of SGLT2 inhibitor trials.

David Z I Cherney et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.